NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free BTAI Stock Alerts $2.69 -0.28 (-9.43%) (As of 02:27 PM ET) Add Compare Share Share Today's Range$2.69▼$2.9950-Day Range$2.55▼$3.5952-Week Range$1.91▼$29.56Volume803,460 shsAverage Volume1.32 million shsMarket Capitalization$99.61 millionP/E RatioN/ADividend YieldN/APrice Target$16.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioXcel Therapeutics alerts: Email Address BioXcel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside510.0% Upside$16.71 Price TargetShort InterestHealthy10.54% of Float Sold ShortDividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews Sentiment0.70Based on 19 Articles This WeekInsider TradingSelling Shares$17,046 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.46) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.33 out of 5 starsMedical Sector116th out of 909 stocksPharmaceutical Preparations Industry41st out of 423 stocks 3.2 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted10.54% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 20.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for BioXcel Therapeutics is -1.13. Previous Next 2.6 News and Social Media Coverage News SentimentBioXcel Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for BioXcel Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 14 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,046.00 in company stock.Percentage Held by Insiders35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.68% of the stock of BioXcel Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.46) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About BioXcel Therapeutics Stock (NASDAQ:BTAI)BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Read More BTAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTAI Stock News HeadlinesApril 9, 2024 | insidertrades.comInsider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Sells 5,268 Shares of StockApril 24, 2024 | globenewswire.comBioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 24, 2024 | americanbankingnews.comBioXcel Therapeutics' (BTAI) Buy Rating Reaffirmed at HC WainwrightApril 23, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI™April 22, 2024 | globenewswire.comBioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialApril 19, 2024 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Recommendation of "Hold" from AnalystsApril 19, 2024 | americanbankingnews.comQ1 2024 Earnings Estimate for BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Issued By HC WainwrightApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 18, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for BioXcel Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:BTAI)April 17, 2024 | investing.comBioXcel Therapeutics stock target cut, retains buy ratingApril 17, 2024 | msn.comBioXcel Therapeutics (BTAI) Price Target Decreased by 9.82% to 10.71April 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory PotentialApril 12, 2024 | investing.comBioXcel Therapeutics to begin phase 3 trial for Alzheimer's treatmentApril 11, 2024 | investing.comBioXcel Therapeutics CCO sells $2.6k in stockApril 10, 2024 | uk.investing.comBioXcel Therapeutics CSO sells shares worth over $2.8kApril 10, 2024 | investing.comBioxcel Therapeutics exec sells over $400 in stockApril 10, 2024 | investing.comBioXcel Therapeutics CEO sells shares worth over $13,000April 10, 2024 | finance.yahoo.comBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaApril 10, 2024 | globenewswire.comBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's DementiaMarch 25, 2024 | globenewswire.comBioXcel Therapeutics Announces $25 Million Registered Direct OfferingMarch 24, 2024 | finance.yahoo.comBioXcel Therapeutics Full Year 2023 Earnings: Revenues DisappointMarch 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 ExpansionMarch 15, 2024 | au.news.yahoo.comTapeworm eggs found in brain of man with penchant for 'undercooked' baconMarch 15, 2024 | markets.businessinsider.comBioXcel Gets European Patent For Sublingual Dexmedetomidine To Treat Agitation In Dementia PatientsMarch 15, 2024 | markets.businessinsider.comBioxcel Therapeutics: Hold Rating Amid Financial and Operational UncertaintiesMarch 15, 2024 | tmcnet.comBioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineSee More Headlines Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/24/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BTAI CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees74Year Founded2017Price Target and Rating Average Stock Price Target$16.71 High Stock Price Target$40.00 Low Stock Price Target$4.00 Potential Upside/Downside+462.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,050,000.00 Net Margins-12,974.86% Pretax Margin-12,974.86% Return on Equity-890.63% Return on Assets-144.88% Debt Debt-to-Equity RatioN/A Current Ratio2.65 Quick Ratio2.57 Sales & Book Value Annual Sales$1.38 million Price / Sales79.70 Cash FlowN/A Price / Cash FlowN/A Book Value($1.89) per share Price / Book-1.57Miscellaneous Outstanding Shares37,030,000Free Float19,630,000Market Cap$109.98 million OptionableOptionable Beta0.40 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, President, & Director Comp: $1.76MMr. Javier Rodriguez (Age 51)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $638.88kMr. Matthew Wiley (Age 51)Senior VP & Chief Commercial Officer Comp: $620.12kMr. Richard I. Steinhart MBA (Age 67)Senior VP & CFO Comp: $404kDr. Frank D. Yocca Ph.D. (Age 67)Senior VP & Chief Scientific Officer Comp: $452.58kDr. Vincent J. O'Neill B.Sc. (Age 55)M.D., M.R.C.P., Executive VP and Chief of Product Development & Medical Officer Comp: $510.17kDr. Chetan D. Lathia Ph.D.Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsDr. Robert Risinger M.D.Chief Medical Officer - NeuroscienceMore ExecutivesKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTSELLAS Life Sciences GroupNASDAQ:SLSDiaMedica TherapeuticsNASDAQ:DMACAllakosNASDAQ:ALLKBeyondSpringNASDAQ:BYSIView All CompetitorsInsiders & InstitutionsVimal MehtaSold 5,268 sharesTotal: $13,802.16 ($2.62/share)Vincent O'neillSold 165 sharesTotal: $432.30 ($2.62/share)Richard I SteinhartSold 1,069 sharesTotal: $2,811.47 ($2.63/share)Virtu Financial LLCBought 59,514 shares on 2/26/2024Ownership: 0.196%Pennant Investors LPBought 83,900 shares on 2/14/2024Ownership: 0.276%View All Insider TransactionsView All Institutional Transactions BTAI Stock Analysis - Frequently Asked Questions Should I buy or sell BioXcel Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares. View BTAI analyst ratings or view top-rated stocks. What is BioXcel Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued 1 year price objectives for BioXcel Therapeutics' stock. Their BTAI share price targets range from $4.00 to $40.00. On average, they expect the company's share price to reach $16.71 in the next twelve months. This suggests a possible upside of 510.0% from the stock's current price. View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts. How have BTAI shares performed in 2024? BioXcel Therapeutics' stock was trading at $2.95 at the beginning of 2024. Since then, BTAI shares have decreased by 7.1% and is now trading at $2.74. View the best growth stocks for 2024 here. Are investors shorting BioXcel Therapeutics? BioXcel Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decrease of 20.7% from the March 15th total of 3,140,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is currently 1.7 days. Currently, 10.5% of the shares of the stock are short sold. View BioXcel Therapeutics' Short Interest. When is BioXcel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BTAI earnings forecast. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.22. The firm earned $0.38 million during the quarter, compared to analyst estimates of $1.17 million. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative trailing twelve-month return on equity of 890.63%. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). When did BioXcel Therapeutics IPO? BioXcel Therapeutics (BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTAI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Goldtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.